OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, has been developed to enable a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is able to increase the efficacy and/or reduce the toxicity of almost any anti-cancer agent and can be used across the majority of the most challenging solid tumour cancers.
The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation of active drug delivery to the tumour on-screen in real time.
Based on ground-breaking technological advances, invented at the University of Oxford’s Institute of Biomedical Engineering, SonoTran maximises the dose and distribution of anti-cancer agents throughout solid tumours. This increases the possibility of cancer patients world-wide benefiting from these potentially life-changing therapies.
OxSonics is based in Oxford in the UK.